Revance Therapeutics, Inc. (NASDAQ: RVNC) Securities Fraud Class Action

Case Background:
This is a federal securities fraud class action lawsuit on behalf of those who purchased or otherwise acquired Revance Therapeutics, Inc. (“Revance”) (NASDAQ: RVNC) securities between August 5, 2021 and October 15, 2021, inclusive (the “Class Period”).

The complaint alleges that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) quality control deficiencies existed at Revance’s manufacturing facility for DAXI; (2) the foregoing deficiencies decreased the likelihood that the FDA would approve the DAXI BLA in its current form; (3) accordingly, it was unlikely that the DAXI BLA would obtain FDA approval within the timeframe Revance had represented to investors; and (4) as a result, Revance’s public statements were materially false and/or misleading at all relevant times.

Current Status of Case:
On January 17, 2025, the Court granted Defendants’ Motion and dismissed the case. On February 18, 2025, the Lead Plaintiff filed a Notice of Appeal. The United States Court of Appeals for the Ninth Circuit dismissed Lead Plaintiffs’ Appeal on August 13, 2025, in accordance with the parties contemplated settlement. This action is ongoing.

If you wish to discuss this action or have any questions, please contact Kessler Topaz Meltzer & Check, LLP: Jon Naji, Esq. (484) 270-1453; toll-free at (844) 887-9500; or via e-mail at [email protected]. If you would like additional information about the suit, please click on the link “Submit Your Information” above and fill out the form as promptly as possible.